107 related articles for article (PubMed ID: 25347426)
1. The deregulated promoter methylation of the Polo-like kinases as a potential biomarker in hematological malignancies.
Ward A; Sivakumar G; Kanjeekal S; Hamm C; Labute BC; Shum D; Hudson JW
Leuk Lymphoma; 2015 Jul; 56(7):2123-33. PubMed ID: 25347426
[TBL] [Abstract][Full Text] [Related]
2. p53-Dependent and cell specific epigenetic regulation of the polo-like kinases under oxidative stress.
Ward A; Hudson JW
PLoS One; 2014; 9(1):e87918. PubMed ID: 24498222
[TBL] [Abstract][Full Text] [Related]
3. Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer.
Zeng Y; Li N; Liu W; Zeng M; Cheng J; Huang J
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2447-2460. PubMed ID: 32627077
[TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase and its inhibitors: Ready for the match to start?
Palmisiano ND; Kasner MT
Am J Hematol; 2015 Nov; 90(11):1071-6. PubMed ID: 26294255
[TBL] [Abstract][Full Text] [Related]
5. Identification and assessment of PLK1/2/3/4 in lung adenocarcinoma and lung squamous cell carcinoma: Evidence from methylation profile.
Deng S; Lu X; Zhang Z; Meng R; Li M; Xia S
J Cell Mol Med; 2021 Jul; 25(14):6652-6663. PubMed ID: 34080290
[TBL] [Abstract][Full Text] [Related]
6. Polo-like kinase 1 expression is suppressed by CCAAT/enhancer-binding protein α to mediate colon carcinoma cell differentiation and apoptosis.
Dasgupta N; Thakur BK; Ta A; Das S; Banik G; Das S
Biochim Biophys Acta Gen Subj; 2017 Jul; 1861(7):1777-1787. PubMed ID: 28341486
[TBL] [Abstract][Full Text] [Related]
7. PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis.
Pezuk JA; Brassesco MS; de Oliveira RS; Machado HR; Neder L; Scrideli CA; Tone LG
Childs Nerv Syst; 2017 Apr; 33(4):609-615. PubMed ID: 28283778
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies.
Syed N; Smith P; Sullivan A; Spender LC; Dyer M; Karran L; O'Nions J; Allday M; Hoffmann I; Crawford D; Griffin B; Farrell PJ; Crook T
Blood; 2006 Jan; 107(1):250-6. PubMed ID: 16160013
[TBL] [Abstract][Full Text] [Related]
9. Functions of Polo-Like Kinases: A Journey From Yeast To Humans.
Vaid R; Sharma N; Chauhan S; Deshta A; Dev K; Sourirajan A
Protein Pept Lett; 2016; 23(2):185-97. PubMed ID: 26786872
[TBL] [Abstract][Full Text] [Related]
10. The expression of RUNDC3B is associated with promoter methylation in lymphoid malignancies.
Burmeister DW; Smith EH; Cristel RT; McKay SD; Shi H; Arthur GL; Davis JW; Taylor KH
Hematol Oncol; 2017 Mar; 35(1):25-33. PubMed ID: 26011749
[TBL] [Abstract][Full Text] [Related]
11. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.
Powrózek T; Krawczyk P; Nicoś M; Kuźnar-Kamińska B; Batura-Gabryel H; Milanowski J
Clin Transl Oncol; 2016 Apr; 18(4):398-404. PubMed ID: 26311076
[TBL] [Abstract][Full Text] [Related]
12. Molecular interactions of polo-like kinase 1 in human cancers.
Weng Ng WT; Shin JS; Roberts TL; Wang B; Lee CS
J Clin Pathol; 2016 Jul; 69(7):557-62. PubMed ID: 26941182
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional regulation of human polo-like kinases and early mitotic inhibitor.
Tategu M; Nakagawa H; Sasaki K; Yamauchi R; Sekimachi S; Suita Y; Watanabe N; Yoshid K
J Genet Genomics; 2008 Apr; 35(4):215-24. PubMed ID: 18439978
[TBL] [Abstract][Full Text] [Related]
14. Aberrant methylation of Polo-like kinase CpG islands in Plk4 heterozygous mice.
Ward A; Morettin A; Shum D; Hudson JW
BMC Cancer; 2011 Feb; 11():71. PubMed ID: 21324136
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
[TBL] [Abstract][Full Text] [Related]
16. Methylation of PLK-1 Potentially Drives Bendamustine Resistance in Leukemia Cells.
Itabashi T; Ueda T; Fukunaga R; Asano T; Itoh Y
J Nippon Med Sch; 2024 May; 91(2):162-171. PubMed ID: 38072417
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.
Takahashi Y; Miyoshi Y; Takahata C; Irahara N; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2005 Feb; 11(4):1380-5. PubMed ID: 15746036
[TBL] [Abstract][Full Text] [Related]
18. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells.
Masala E; Valencia A; Buchi F; Nosi D; Spinelli E; Gozzini A; Sassolini F; Sanna A; Zecchi S; Bosi A; Santini V
Leuk Res; 2012 Oct; 36(10):1290-5. PubMed ID: 22742816
[TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase inhibitors in hematologic malignancies.
Talati C; Griffiths EA; Wetzler M; Wang ES
Crit Rev Oncol Hematol; 2016 Feb; 98():200-10. PubMed ID: 26597019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
